| Autoantibodies against type I IFNs in patients with life-threatening COVID-19 P Bastard, LB Rosen, Q Zhang, E Michailidis, HH Hoffmann, Y Zhang, ... Science 370 (6515), eabd4585, 2020 | 2756 | 2020 |
| Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Q Zhang, P Bastard, Z Liu, J Le Pen, M Moncada-Velez, J Chen, M Ogishi, ... Science 370 (6515), eabd4570, 2020 | 2358 | 2020 |
| Convergent antibody responses to SARS-CoV-2 in convalescent individuals DF Robbiani, C Gaebler, F Muecksch, JCC Lorenzi, Z Wang, A Cho, ... Nature 584 (7821), 437-442, 2020 | 2099 | 2020 |
| Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants Y Weisblum, F Schmidt, F Zhang, J DaSilva, D Poston, JCC Lorenzi, ... elife 9, e61312, 2020 | 1537 | 2020 |
| Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses F Schmidt, Y Weisblum, F Muecksch, HH Hoffmann, E Michailidis, ... Journal of Experimental Medicine 217 (11), e20201181, 2020 | 596 | 2020 |
| Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 540 | 2021 |
| Enhanced SARS-CoV-2 neutralization by dimeric IgA Z Wang, JCC Lorenzi, F Muecksch, S Finkin, C Viant, C Gaebler, ... Science translational medicine 13 (577), eabf1555, 2021 | 465 | 2021 |
| Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks WM Schneider, JM Luna, HH Hoffmann, FJ Sánchez-Rivera, AA Leal, ... Cell 184 (1), 120-132. e14, 2021 | 363 | 2021 |
| CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus V Ramanan, A Shlomai, DBT Cox, RE Schwartz, E Michailidis, A Bhatta, ... Scientific reports 5 (1), 10833, 2015 | 340 | 2015 |
| LY6E impairs coronavirus fusion and confers immune control of viral disease S Pfaender, KB Mar, E Michailidis, A Kratzel, IN Boys, P V’kovski, W Fan, ... Nature microbiology 5 (11), 1330-1339, 2020 | 213 | 2020 |
| Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine P Bastard, E Michailidis, HH Hoffmann, M Chbihi, T Le Voyer, J Rosain, ... Journal of Experimental Medicine 218 (4), e20202486, 2021 | 183 | 2021 |
| Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors HH Hoffmann, FJ Sánchez-Rivera, WM Schneider, JM Luna, ... Cell host & microbe 29 (2), 267-280. e5, 2021 | 167 | 2021 |
| The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies J Manry, P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, ... Proceedings of the National Academy of Sciences 119 (21), 2022 | 164 | 2022 |
| Mechanism of inhibition of HIV-1 reverse transcriptase by 4′-ethynyl-2-fluoro-2′-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor E Michailidis, B Marchand, EN Kodama, K Singh, M Matsuoka, KA Kirby, ... Journal of Biological Chemistry 284 (51), 35681-35691, 2009 | 163 | 2009 |
| The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes JE Tavis, X Cheng, Y Hu, M Totten, F Cao, E Michailidis, R Aurora, ... PLoS pathogens 9 (1), e1003125, 2013 | 126 | 2013 |
| 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms E Michailidis, AD Huber, EM Ryan, YT Ong, MD Leslie, KB Matzek, ... Journal of Biological Chemistry 289 (35), 24533-24548, 2014 | 119 | 2014 |
| Inborn errors of OAS–RNase L in SARS-CoV-2–related multisystem inflammatory syndrome in children D Lee, J Le Pen, A Yatim, B Dong, Y Aquino, M Ogishi, R Pescarmona, ... Science 379 (6632), eabo3627, 2022 | 116 | 2022 |
| Structural aspects of drug resistance and inhibition of HIV-1 reverse transcriptase K Singh, B Marchand, KA Kirby, E Michailidis, SG Sarafianos Viruses 2 (2), 606-638, 2010 | 107 | 2010 |
| Inherited IL-18BP deficiency in human fulminant viral hepatitis S Belkaya, E Michailidis, CB Korol, M Kabbani, A Cobat, P Bastard, ... Journal of Experimental Medicine 216 (8), 1777-1790, 2019 | 105 | 2019 |
| Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) ZL Salie, KA Kirby, E Michailidis, B Marchand, K Singh, LC Rohan, ... Proceedings of the National Academy of Sciences 113 (33), 9274-9279, 2016 | 101 | 2016 |
